February 6, 2020
— Bharat Book Bureau Provides the Trending Market Research Report on “Europe Flu Vaccine Market Report 2019 ”under Life Sciences Category. The report offers a collection of superior market research, market analysis, competitive intelligence and Market reports.
In this report, EMEA Flu Vaccine Market will reach 1185.08 Million USD by the end of 2022 with a CAGR of 7.94%
The EMEA Flu Vaccine market was valued at 808.63 Million USD in 2017 and will reach 1185.08 Million USD by the end of 2022, growing at a CAGR of 7.94% during 2017-2022.
Influenza vaccines, also known as flu shots, are vaccines that protect against influenza. A new version of the vaccine is developed twice a year as the influenza virus rapidly changes. Most provide modest to high protection against influenza; however, each year this varies. Evidence in adults over 65 years old is poor. They decrease the number of missed days of work by a half day on average. Vaccinating children may protect those around them.
Flu Vaccine can be divided into four categories: Whole Virus Vaccines type, Split Virus Vaccines type, Subunit Vaccines type and Live Attenuated Virus Vaccines type. Whole Virus Vaccines type accounted for the highest proportion in sales market, with a figure of 43.15% in 2017, followed by Subunit Vaccines, account for 19.57% and Split Virus Vaccines type accounted for 18.93%.
Request a free sample copy Flu Vaccine Market Report @
The sales market share of EMEA Flu Vaccine in For Children (6 months to 3 years) use and For Adults and Children over 3 years use has been stable year by year, at 23.21% and 76.79% respectively in 2017, and for several consecutive years, the amplitude was within one percent. This indicates that the segment of the Flu Vaccine in the EMEA market tends to be fixed without great changes. Among them, the Flu Vaccine market has the most promising sales prospects in For Adults and Children over 3years use.
This research center data shows that Europe is the biggest contributor to the Flu Vaccine revenue market, accounted for 81.08% of the total EMEA market with a revenue of 655.61 million USD in 2017, followed by Middle East, 11.75% with a revenue of 94.99 million USD.
Market competition is not intense. CSL, GSK, Sanofi Pasteur, Mylan, AstraZeneca, Pfizer and Johnson & Johnson, etc. are the leaders of the industry in the EMEA, with high-end customers in the Flu Vaccine market.
Geographically, this report split Europe into several key Regions, with sales (K Units), revenue (Million USD), market share and growth rate of Flu Vaccine for these regions, from 2014 to 2022 (forecast), including
Europe Flu Vaccine market competition by top manufacturers/players, with Flu Vaccine sales volume, price, revenue (Million USD) and market share for each manufacturer/player; the top players including
Johnson & Johnson
On the basis of product, this report displays the sales volume (K Units), revenue (Million USD), product price (USD/Unit), market share and growth rate of each type, primarily split into
Whole Virus Vaccines
Split Virus Vaccines
Live Attenuated Virus Vaccines
On the basis on the end users/applications, this report focuses on the status and outlook for major applications/end users, sales volume (K Units), market share and growth rate of Flu Vaccine for each application, including
For Children (6 months to 3 years)
For Adults and Children over 3 years
If you have any special requirements, please let us know and we will offer you the report as you want.
Browse our full report with Table of Content :
About - Bharat Book Bureau:
Bharat Book is Your One-Stop-Shop with an exhaustive coverage of 4,80,000 reports and insights that includes latest Market Study, Market Trends & Analysis, Forecasts Customized Intelligence, Newsletters and Online Databases. Overall a comprehensive coverage of major industries with a further segmentation of 100+ subsectors.
Contact us at:
Bharat Book Bureau
Tel: +91 22 27810772 / 27810773
Email: [email protected]